Teva enters settlement with Novo Nordisk to sell Victoza generic
Danish pharmaceutical company Novo Nordisk and generics maker Teva have reached a settlement in their US dispute over Victoza.
Federal Circuit rules ‘treatment claims’ are patent eligible
The US Court of Appeals for the Federal Circuit has warned against implementing “too broad” an interpretation of the Alice test as it ruled that “treatment claims” were eligible for patenting.
Federal Circuit sends Allergan’s patent dispute back to district court
A district court must revisit its decision that one of Allergan’s patents is valid and was not infringed by a competitor.
WHO and UN actions undermine IP and hurt innovation, warns PhRMA
Supranational organisations such as the World Health Organization and the United Nations Development Program are promoting acts, policies and practices that prevent biopharmaceutical innovators from securing and maintaining patents.
Senior counsel at Bayer highlights pharmaceutical TM challenges
Doctors’ handwriting poses a significant challenge to the registration of pharmaceutical trademarks, according to a senior counsel at German pharmaceutical company Bayer.
PTAB invalidates Prevnar 13 patent
American pharmaceutical company Merck & Co. has secured a victory against its rival Pfizer in an inter partes review of a patent concerning Prevnar 13, the biggest-selling vaccine in the world.
National Cancer Institute’s director named as acting FDA chief
The Trump administration has named Ned Sharpless, director of the National Cancer Institute, as the Food and Drug Administration's (FDA) acting commissioner.
LSIPR webinar: No end in sight for CRISPR IP saga, says HGF
Press releases in recent months that suggest the CRISPR IP saga is about to end are too optimistic and miss out many of the nuances of the current situation, according to Claire Irvine, partner at HGF.
India cuts Monsanto GM cotton seed royalties by almost half
India’s government has cut the royalties its local seed companies and farmers pay to Monsanto by almost 50%.
Novartis fails to secure ‘smart’ TM for contact lenses
Switzerland-based Novartis today, March 12, failed to convince the EU General Court that its ‘Smartsurface’ trademark should be registered for contact lenses.
